DEEPPATH LTD
DeepPath Ltd is a UK MedTech company that develops DeepPath-LYDIA, a CE-Marked AI system for detecting metastases in H&E stained digital pathology slides, sold to hospital pathology departments and academic medical centers across the UK, Netherlands, and additional European and US markets.
- Company typePrivate
- Founded2017
- HeadquartersManchester, United Kingdom
- Headcount—
- GTM typeB2B
- OfferingSoftware
What DEEPPATH LTD does
DeepPath Ltd is a UK MedTech company founded in 2017 and headquartered at 3 Hardman Square, Spinningfields, Manchester. It develops DeepPath-LYDIA, a CE-Marked AI-powered decision support system (Class I in-vitro diagnostic under IVDD, certified May 2022) that assists histopathologists in detecting metastases on digitised whole slide images of H&E stained lymph node tissue. A single deep learning pipeline screens four cancer types—breast, colon, lung cancer and melanoma—covering approximately 43% of total cancer incidence, processing each slide in under 2.5 minutes at greater than 99% sensitivity and fewer than four false-positive tumour segments per lymph node.
The product is offered as either standalone software with basic case management or as an embedded component within third-party PACS systems, with cloud or on-premise deployment and support for Hamamatsu, 3D-Histech, Leica, Roche and Philips WSI formats. DeepPath monetises through annual unlimited-user subscription licences, a pay-as-you-go per-slide model, and a free trial for prospect validation, distributing via direct enterprise sales to hospital pathology departments and NHS trusts alongside its position as the first lymph-node metastasis detection solution featured on the Sectra Amplifier Marketplace.
Operationally, the company has secured its first named production deployment at UMC Utrecht (live October 2024, fully integrated into Sectra PACS) and is part of the PathLAKE NHS consortium targeting 17 million patients across Southern England. Capital structure is grant-led rather than VC-backed: a €4 million EIC Pathfinder grant (May 2022) via a consortium with MIDA Biotech, Leiden University and MIRCOD LLC, alongside earlier-stage support from SBRI Healthcare and the National Bank of Greece's nbgseeds program. No revenue, headcount, or venture equity rounds are disclosed; Konstantinos Vougas serves as Managing Director of the Greek operating entity DeepPath Monoprosopi IKE.
DEEPPATH LTD firmographics
Firmographics- Name
- DEEPPATH LTD
- Legal name
- DeepMed IO Ltd
- Website
- https://deeppath.io
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Short description
- DeepPath Ltd is a UK MedTech company that develops DeepPath-LYDIA, a CE-Marked AI system for detecting metastases in H&E stained digital pathology slides, sold to hospital pathology departments and academic medical centers across the UK, Netherlands, and additional European and US markets.
- Ownership category
- akta.pro rank
DEEPPATH LTD industry classification
Industry- Product category
- Digital Pathology Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Health Services (8000), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
Keywords
Where DEEPPATH LTD is headquartered
LocationHeadquarters
- HQ city
- Manchester
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
DEEPPATH LTD business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations
Revenue model
- Software Licensing (Yearly Subscription): Yearly licence with unlimited users based on system usage as estimated from past data. Provides ongoing access to DeepPath-LYDIA with support and updates.
- Pay-as-You-Go Usage: Fixed cost per microscope slide analysed. Flexible consumption-based model that allows customers to pay only for actual usage.
- Free Trial: Customers can try LYDIA on their samples for free before committing to a paid licensing option.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Free Trial - Try before you buy |
| Subscription | Annual | Yearly Licence - Unlimited users |
| Usage-based | Pay-as-you-go | Pay as You Use - Per slide pricing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
DEEPPATH LTD product offering
Product offeringCore offering
DeepPath develops and sells DeepPath-LYDIA, a CE-Marked AI-powered clinical decision support system that detects metastatic regions on digitised Whole Slide Images of H&E stained lymph node tissue for breast, colon, lung cancer and melanoma. The product is offered as standalone software with basic case management or as an integrated component within third-party PACS systems (notably Sectra), with cloud or on-premise deployment options. Revenue is generated via annual enterprise licences (unlimited users) and pay-per-slide usage pricing, supplemented by a free trial.
Product overview
DeepPath is a MedTech company offering a single unified AI product: DeepPath – LYDIA. This AI-powered decision support system is designed to assist histopathologists in cancer staging by detecting metastatic regions on digitised microscope slides. The system is CE-Marked as an in-vitro diagnostic product and can be deployed either on-cloud or on-premise. It is offered either as standalone software with basic case management or as an integrated component within third-party Picture Archiving and Communication Systems (PACS), particularly the Sectra Digital Pathology platform.
Differentiator
Problem solved
Functional benefit
Brands
- DeepPath-LYDIA: CE-Marked AI-powered decision support system for detecting metastases on digitised microscope slides of H&E stained Lymph Nodes, supporting breast, colon, lung cancer and melanoma detection.
Products and services
- DeepPath – LYDIA AI-powered CE-Marked decision support system that analyses digitised Whole Slide Images of H&E stained lymph node tissue to detect metastatic regions across breast, colon, lung cancer and melanoma. Generates probabilistic heatmaps and tumour segments, processes slides in under 2.5 minutes with sensitivity above 99%, and is offered either as standalone software with basic case management or as an integrated component within PACS systems such as Sectra. Sold to hospital pathology departments, NHS Trusts, and academic medical centers via annual subscription or pay-per-slide pricing.
Quantifiable outcome
- Up to 5x acceleration of diagnostic process
- +4 more outcomes
Companies that use DEEPPATH LTD
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
DEEPPATH LTD technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability2 records
Feature4 records
DEEPPATH LTD partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered key, flagship, core and minor.
- UMC UtrechtkeyUniversity Medical Center Utrecht deployed DeepPath-LYDIA in production, fully integrated into the Sectra PACS system. UMC Utrecht are pioneers in digital pathology and serve as a reference customer for the technology.
- PathLAKE (NHS Trusts Consortium)flagshipPathLAKE consortium of NHS Trusts in Southern England has DeepPath-LYDIA under procurement. This represents one of the world's largest clinical implementations of digital pathology and AI, targeting 17 million NHS patients.
- Sectra (Spectra Amplifier)coreDeepPath-LYDIA completed integration with Sectra Digital Pathology solution and is featured on the Sectra Amplifier Marketplace. DeepPath is a certified Sectra Amplifier Integrator. The integration allows histopathologists to access AI analysis without leaving the Sectra workflow.
- MIDA Biotech B.V. (Orgenesis Inc.)coreMIDA Biotech B.V. (an Orgenesis Inc. company) is a consortium partner in the €4m Pathfinder grant for AI-powered autologous IPCS manufacturing platform to democratize personalized cell therapy.
- Leiden UniversitycoreLeiden University is a consortium partner in the €4m Pathfinder grant for AI-powered platform development to democratize autologous cell therapy manufacturing.
- MIRCOD LLCcoreMIRCOD LLC is a consortium partner in the €4m Pathfinder grant for AI-powered platform development to democratize autologous cell therapy manufacturing.
- The Christie NHS Foundation TrustkeyMajor UK cancer treatment hospital collaborating with DeepPath on histopathology AI development and validation.
- UCL (University College London)keyLeading UK university with medical school collaborating with DeepPath on histopathology AI research and development.
- Manchester University NHS Foundation TrustkeyMajor NHS Trust in Manchester collaborating with DeepPath on digital pathology AI implementation.
- NYU (New York University)keyInternational academic partner collaborating with DeepPath on histopathology AI research and development.
- University of AthensminorGreek university collaborating with DeepPath on histopathology AI research.
- Manchester Cancer Research CenterminorCancer research center collaborating with DeepPath on histopathology AI for cancer diagnostics.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
DEEPPATH LTD competitors and assessment
Company assessmentDirect peers
- Ibex Medical Analytics: Ibex builds AI-based cancer diagnostics for pathology, including breast and prostate cancer detection deployed in routine clinical use across multiple health systems. Comparable as a CE-marked AI pathology decision-support vendor with multi-cancer ambitions and similar hospital pathology customer base.
- PathAI: PathAI applies deep learning to histopathology for cancer diagnosis and biomarker discovery, partnering with academic medical centers and biopharma. Comparable AI pathology peer with similar use cases in oncology diagnostics and a comparable research-and-commercial footprint.
- Lunit: Lunit provides AI solutions for cancer diagnostics including Lunit SCOPE, a CE-marked AI for pathology biomarker analysis. Comparable as an AI pathology vendor with multi-cancer products targeting hospital and reference lab customers globally.
- Mindpeak: Mindpeak develops AI-based image analysis for histopathology, including breast and prostate cancer detection, integrated with major PACS and slide scanner vendors. Comparable as a European AI pathology peer targeting pathology department workflows.
- Paige.AI: Paige develops AI-powered clinical decision support for digital pathology, with FDA-cleared products for prostate and breast cancer detection. Directly comparable as an AI pathology decision-support vendor serving hospital pathology departments with deep learning on whole slide images.
- Qritive: Qritive builds AI-powered clinical decision support tools for pathology across multiple cancer types including breast, lung, colon, and prostate. Directly comparable in offering AI decision support for multi-cancer metastasis detection in hospital pathology workflows.
- Proscia: Proscia offers a digital pathology platform with embedded AI applications for cancer detection, including Concentriq for diagnostic workflows. Comparable as a digital pathology platform vendor offering AI decision-support capabilities to hospital pathology departments.
- Owkin: Owkin develops AI for pathology and oncology, including MSIntuit, an AI diagnostic for microsatellite instability in colorectal cancer. Comparable as an AI-on-histopathology vendor targeting oncology decision support and integrated PACS workflows.
Emerging players
- Aiosyn: Aiosyn is an emerging AI pathology company focused on computational pathology for kidney and prostate cancer diagnostics. Comparable emerging peer with similar deep-learning approach to cancer detection on whole slide images for hospital pathology customers.
Others
- Sectra: Sectra is the digital pathology platform provider whose Amplifier Marketplace distributes DeepPath-LYDIA. While not a direct AI competitor, Sectra is the dominant distribution partner and infrastructure provider and is highly relevant as both channel partner and platform dependency.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
DEEPPATH LTD social profiles
Digital presenceDEEPPATH LTD compliance and trust
Trust signalCompliance1 record
DEEPPATH LTD financial estimates
Financial estimateRevenue estimate
Valuation estimate
DEEPPATH LTD leadership team
Management profileNumber of profiles
Profiles1 record
DEEPPATH LTD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DEEPPATH LTD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DEEPPATH LTD
What does DEEPPATH LTD do?
DeepPath develops and sells DeepPath-LYDIA, a CE-Marked AI-powered clinical decision support system that detects metastatic regions on digitised Whole Slide Images of H&E stained lymph node tissue for breast, colon, lung cancer and melanoma. The product is offered as standalone software with basic case management or as an integrated component within third-party PACS systems (notably Sectra), with cloud or on-premise deployment options. Revenue is generated via annual enterprise licences (unlimited users) and pay-per-slide usage pricing, supplemented by a free trial.
Is DEEPPATH LTD a public or private company?
DEEPPATH LTD is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was DEEPPATH LTD founded?
DEEPPATH LTD was founded in 2017.
Where is DEEPPATH LTD based?
DEEPPATH LTD is headquartered in Manchester, United Kingdom, in the Europe region.
How does DEEPPATH LTD make money?
Three revenue lines are on record. Software Licensing (Yearly Subscription) is the primary driver. The others are pay-as-You-Go Usage and free Trial.
Who are DEEPPATH LTD's main competitors?
Direct peers on record are Ibex Medical Analytics, PathAI, Lunit, Mindpeak, Paige.AI, Qritive, Proscia and Owkin. Aiosyn is listed as an emerging player. Sectra is listed as an others.
Does DEEPPATH LTD have an API?
No public API is recorded for DEEPPATH LTD.
What industry is DEEPPATH LTD in?
DEEPPATH LTD's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support. Its NAICS code is 5132 and its SIC code is 8000.